Download PDF
Planta Med
DOI: 10.1055/a-2320-8822
Original Papers

Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion

Nica Classen
2   Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Germany
,
Thanet Pitakbut 
1   Technical Biochemistry Laboratory, Faculty of Biochemical and Chemical Engineering, Technical University of Dortmund, Germany
,
Michael Schöfbänker
3   Institute of Virology Münster (IVM), University of Münster, Germany
,
Joachim Kühn
3   Institute of Virology Münster (IVM), University of Münster, Germany
,
Eike R. Hrincius
3   Institute of Virology Münster (IVM), University of Münster, Germany
,
Stephan Ludwig
3   Institute of Virology Münster (IVM), University of Münster, Germany
,
Andreas Hensel 
2   Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Germany
,
Oliver Kayser 
1   Technical Biochemistry Laboratory, Faculty of Biochemical and Chemical Engineering, Technical University of Dortmund, Germany
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The search for new active substances against SARS-CoV-2 is still a central challenge after the COVID-19 pandemic. Antiviral agents to complement vaccination are an important pillar in the clinical situation. Selected cannabinoids such as cannabigerol, cannabicyclol, cannabichromene, and cannabicitran from Cannabis sativa and synthetic homologues of cannabigerol and cannabicyclol were evaluated for effects on the cell viability of Vero cells (CC50 of cannabigerol and cannabicyclol 40 resp. 38 µM) and reduced virus entry of vesicular stomatitis pseudotyped viruses with surface-expressed SARS-CoV-2 spike protein at 20 µM. In addition to a reduction of pseudotyped virus entry, a titer reduction assay on Vero cells after preincubation of Wuhan SARS-CoV-2 significantly confirmed antiviral activity. Investigations on the molecular targets addressed by cannabigerol and cannabicyclol indicated that both compounds are inhibitors of SARS-CoV-2 spike protein-mediated membrane fusion, as could be shown by a virus-free reporter fusion inhibition assay (EC50 for cannabigerol 5.5 µM and for cannabicyclol 10.8 µM) and by monitoring syncytia formation in Vero reporter cells. Selectivity indices were calculated as 7.4 for cannabigerol and 3.5 for cannabicyclol. Systematic semisynthetic alterations of cannabigerol and cannabicyclol indicated that the side chains of both compounds do not contribute to the observed anti-membrane fusion activity.

Keywords

COVID-19 - SARS-CoV-2 - Cannabis sativa - Cannabaceae - cannabinoids - cannabigerol - cannabicyclol - membrane fusion - virulence factors

Supporting Information

    The data that support the findings of this study are available as Supporting Information.

  • Supporting Information


Publication History

Received: 24 January 2024

Accepted: 28 April 2024

Article published online:
17 June 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Evans F. Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Med 1991; 57: S60-S67
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic use in clinical practice. Int J Mol Sci 2022; 23: 3344
    CrossrefPubMedGoogle Scholar
  • 3 Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 2017; 175: 133-150
    CrossrefPubMedGoogle Scholar
  • 4 Nguyen G, Kayser O. Biosynthesis and Chemical Modifications of Minor Cannabinoids. eLS 2020; 1-9
    PubMedGoogle Scholar
  • 5 Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: A unified critical inventory. Nat Prod Rep 2016; 33: 1357-1392
    CrossrefPubMedGoogle Scholar
  • 6 Walsh KB, McKinney AE, Holmes AE. Minor cannabinoids: Biosynthesis, molecular pharmacology and potential therapeutic uses. Front Pharmacol 2021; 12: 777804
    CrossrefPubMedGoogle Scholar
  • 7 Turner SE, Williams CM, Iversen L, Whalley BJ. Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod 2017; 103: 61-101
    PubMedGoogle Scholar
  • 8 Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant – Do they exist?. Br J Pharmacol 2010; 160: 523-529
    CrossrefPubMedGoogle Scholar
  • 9 Hensel A, Bauer R, Heinrich M, Spiegler V, Kayser O, Hempel G, Kraft K. Challenges at the time of COVID-19: Opportunities and innovations in antivirals from nature. Planta Med 2020; 86: 659-664
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Elsohly HN, Turner CE, Clark AM, Elsohly MA. Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J Pharm Sci 1982; 71: 1319-1323
    CrossrefPubMedGoogle Scholar
  • 11 Turner CE, Elsohly MA. Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol 1981; 21: 283S-291S
    CrossrefPubMedGoogle Scholar
  • 12 Van Klingeren B, Ten Ham M. Antibacterial activity of Δ9-tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek 1976; 42: 9-12
    CrossrefPubMedGoogle Scholar
  • 13 Farha MA, El-Halfawy OM, Gale RT, Macnair CR, Carfrae LA, Zhang X, Jentsch NG, Magolan J, Brown ED. Uncovering the hidden antibiotic potential of cannabis. ACS Infect Dis 2020; 6: 338-346
    CrossrefPubMedGoogle Scholar
  • 14 Martinenghi LD, Jønsson R, Lund T, Jenssen H. Isolation, purification, and antimicrobial characterization of cannabidiolic acid and cannabidiol from Cannabis sativa L. Biomolecules 2020; 10: 900
    CrossrefPubMedGoogle Scholar
  • 15 Medveczky MM, Sherwood TA, Klein TW, Friedman H, Medveczky PG. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro . BMC Med 2004; 2: 34
    CrossrefPubMedGoogle Scholar
  • 16 Tagne AM, Pacchetti B, Sodergren M, Sodergren M, Cosentino M, Marino F. Cannabidiol for viral diseases: Hype or hope?. Cannabis Cannabinoid Res 2020; 5: 121-131
    CrossrefPubMedGoogle Scholar
  • 17 Costiniuk CT, Saneei Z, Routy JP, Margolese S, Mandarino E, Singer J, Lebouché B, Cox J, Szabo J, Brouillette MJ, Klein MB, Chomont N, Jenabian MA. Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. BMJ Open 2019; 9: 1-14
    CrossrefPubMedGoogle Scholar
  • 18 Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 2013; (2013) CD005175
    PubMedGoogle Scholar
  • 19 Lowe H, Toyang N, McLaughlin W. Potential of cannabidiol for the treatment of viral hepatitis. Pharmacognosy Res 2017; 9: 116-118
    CrossrefPubMedGoogle Scholar
  • 20 Karmaus PWF, Chen W, Crawford R, Kaplan BLF, Kaminski NE. Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2. Toxicol Sci 2013; 131: 419-433
    CrossrefPubMedGoogle Scholar
  • 21 Tahamtan A, Tavakoli-Yaraki M, Rygiel TP, Mokhtari-Azad T, Salimi V. Effects of cannabinoids and their receptors on viral infections. J Med Virol 2016; 88: 1-12
    CrossrefPubMedGoogle Scholar
  • 22 Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X, Groopman JE. Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium. Genes Cancer 2012; 3: 512-520
    CrossrefPubMedGoogle Scholar
  • 23 Raj V, Park JG, Cho KH, Choi P, Kim T, Ham J, Lee J. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. Int J Biol Macromol 2021; 168: 474-485
    CrossrefPubMedGoogle Scholar
  • 24 Pitakbut T, Nguyen GN, Kayser O. Activity of THC, CBD, and CBN on Human ACE2 and SARS-CoV1/2 Main Protease to Understand Antiviral Defense Mechanism. Planta Med 2022; 88: 1047-1059
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. J Nat Prod 2022; 85: 176-184
    CrossrefPubMedGoogle Scholar
  • 26 Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D, Gabbard JD, Chen SN, Ohtsuki T, Friesen JB, Drayman N, Mohamed A, Dann C, Silva D, Robinson-Mailman L, Valdespino A, Stock L, Suárez E, Jones KA, Azizi SA, Demarco JK, Severson WE, Anderson CD, Millis JM, Dickinson BC, Tay S, Oakes SA, Pauli GF. Palmer KE; National COVID Cohort Collaborative Consortium, Meltzer DO, Randall G, Rosner MR. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv 2022; 8: 6110
    CrossrefPubMedGoogle Scholar
  • 27 Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I, Kovalchuk O. In search of preventative strategies: novel high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY) 2020; 12: 22425-22444
    CrossrefPubMedGoogle Scholar
  • 28 Tamburello M, Salamone S, Anceschi L, Governa P, Brighenti V, Morellini A, Rossini G, Manetti F, Gallinella G, Pollastro F, Pellati F. Antiviral activity of cannabidiolic acid and its methyl ester against SARS-CoV-2. J Nat Prod 2023; 86: 1698-1707
    CrossrefPubMedGoogle Scholar
  • 29 Reyer M. Researchers Recommend Clinical Trials for CBD to Prevent COVID-19 Based on Promising Animal Data. Chicago: The University of Chicago Medicine; 2022
    Google Scholar
  • 30 Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med (Lausanne) 2020; 7: 526
    CrossrefPubMedGoogle Scholar
  • 31 Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology – Current perspectives. Pulmonology 2021; 27: 423-437
    CrossrefPubMedGoogle Scholar
  • 32 Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev 2020; 53: 66-70
    CrossrefPubMedGoogle Scholar
  • 33 Jastrząb A, Jarocka-Karpowicz I, Skrzydlewska E. The origin and biomedical relevance of cannabigerol. Int J Mol Sci 2022; 23: 7929
    CrossrefPubMedGoogle Scholar
  • 34 Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
    CrossrefPubMedGoogle Scholar
  • 35 Mohamed FF, Anhlan D, Schöfbänker M, Schreiber A, Classen N, Hensel A, Hempel G, Scholz W, Kühn J, Hrincius ER, Liudwig S. Hypericum perforatum and its ingredients hypericin and pseudohypericin demonstrate an antiviral activity against SARS-CoV-2. Pharmaceuticals (Basel) 2022; 15: 530
    CrossrefPubMedGoogle Scholar
  • 36 Steinberg TH, Jones LJ, Haugland RP, Singer VL. SYPRO orange and SYPRO red protein gel stains: One-step fluorescent staining of denaturing gels for detection of nanogram levels of protein. Anal Biochem 1996; 239: 223-237
    CrossrefPubMedGoogle Scholar
  • 37 Huynh K, Partch CL. Analysis of protein stability and ligand interactions by thermal shift assay. Curr Protoc Protein Sci 2015; 79: 28.9.1-28.9.14
    CrossrefPubMedGoogle Scholar
  • 38 Classen N, Ulrich D, Hofemeier A, Hennies MT, Hafezi W, Pettke A, Romberg ML, Lorentzen EU, Hensel A, Kühn JE. Broadly applicable, virus-free dual reporter assay to identify compounds interfering with membrane fusion: performance for HSV-1 and SARS-CoV-2. Viruses 2022; 14: 1354
    CrossrefPubMedGoogle Scholar
  • 39 Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F. Cannabinoid receptor type 2: A possible target in SARS-CoV-2 (CoV-19) infection?. Int J Mol Sci 2020; 21: 13809
    CrossrefPubMedGoogle Scholar
  • 40 van Breemen RB, Simchuk D. Antiviral activities of hemp cannabinoids. Clin Sci 2023; 137: 633-643
    CrossrefPubMedGoogle Scholar
  • 41 Sea YL, Gee YJ, Lal SK, Choo WS. Cannabis as antivirals. J Appl Microbiol 2023; 134: lxac036
    CrossrefPubMedGoogle Scholar
  • 42 Liu C, Puopolo T, Li H, Cai A, Seeram NP, Ma H. Identification of SARS-CoV-2 main protease inhibitors from a library of minor cannabinoids by biochemical inhibition assay and surface plasmon resonance characterized binding affinity. Molecules 2022; 27: 6127
    CrossrefPubMedGoogle Scholar
  • 43 Berkhout B, Eggink D, Sanders RW. Is there a future for antiviral fusion inhibitors?. Curr Opin Virol 2012; 2: 50-59
    CrossrefPubMedGoogle Scholar
  • 44 Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv 2019; 5: eaav4580
    CrossrefPubMedGoogle Scholar
  • 45 Ray B, Ali I, Jana S, Mukherjee S, Pal S, Ray S, Schütz M, Marschall M. Antiviral strategies using natural source-derived sulfated polysaccharides in the light of the COVID-19 pandemic and major human pathogenic viruses. Viruses 2022; 14: 35
    CrossrefPubMedGoogle Scholar
  • 46 Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM. Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. J Nat Prod 2008; 71: 1427-1430
    CrossrefPubMedGoogle Scholar
  • 47 Scott C, Hall S, Zhou J, Lehmann C. Cannabinoids and the endocannabinoid system in early SARS-CoV-2 infection and long COVID-19 – A scoping review. J Clin Med 2023; 13: 227
    CrossrefPubMedGoogle Scholar
  • 48 Nguyen GN, Jordan EN, Kayser O. Synthetic strategies for rare cannabinoids derived from Cannabis sativa . J Nat Prod 2022; 85: 1555-1568
    CrossrefPubMedGoogle Scholar
  • 49 Hafezi W, Lorentzen EU, Eing BR, Müller M, King NJC, Klupp B, Mettenleiter TC, Kühn JE. Entry of herpes simplex virus type 1 (HSV-1) into the distal axons of trigeminal neurons favors the onset of nonproductive, silent infection. PLoS Pathog 2012; 8: e1002679
    CrossrefPubMedGoogle Scholar
  • 50 Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280.e8
    CrossrefPubMedGoogle Scholar